CLL/SLL
Clinical trials for CLL/SLL explained in plain language.
Never miss a new study
Get alerted when new CLL/SLL trials appear
Sign up with your email to follow new studies for CLL/SLL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Second chance: new combo aims to control CLL after relapse
Disease control Recruiting nowThis study is for people with chronic lymphocytic leukemia (CLL) whose cancer returned after their first treatment with venetoclax and an antibody. Researchers want to see if a new combination of two drugs, venetoclax and acalabrutinib, can control the disease again. About 60 adu…
Matched conditions: CLL/SLL
Phase: PHASE2 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
New hope for hard-to-treat blood cancers: experimental drug enters human testing
Disease control Recruiting nowThis early-phase study tests a new drug called ZE50-0134 in about 66 adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or certain low-grade lymphomas that have returned or not responded to prior therapies. The main goals are to check the drug's safety and how …
Matched conditions: CLL/SLL
Phase: PHASE1 • Sponsor: Lomond Therapeutics Holdings, Inc. • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
New combo therapy aims to wipe out hidden leukemia cells
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab after standard treatment can help people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) achieve a deeper remission. About 22 adults who have already received at least 12 months of a BTK inhibitor (a…
Matched conditions: CLL/SLL
Phase: PHASE2 • Sponsor: Zulfa Omer • Aim: Disease control
Last updated May 17, 2026 02:01 UTC
-
New drug combo aims to extend life for blood cancer patients
Disease control Recruiting nowThis study tests whether adding a new drug, lisaftoclax, to standard BTK inhibitor therapy can help people with chronic lymphocytic leukemia or small lymphocytic lymphoma live longer without their cancer getting worse. About 400 adults who have already been treated with a BTK inh…
Matched conditions: CLL/SLL
Phase: PHASE3 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated May 17, 2026 02:00 UTC
-
New hope for Tough-to-Treat leukemia: phase 3 trial pits rocbrutinib against pirtobrutinib
Disease control Recruiting nowThis study tests a new drug, rocbrutinib, against another drug, pirtobrutinib, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments. About 306 adults will take one of the two pills daily to s…
Matched conditions: CLL/SLL
Phase: PHASE3 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
New pill takes on tough blood cancers in early human trial
Disease control Recruiting nowThis early-phase study tests an experimental oral drug called LP-168 in about 60 adults with several types of B-cell blood cancers (like lymphoma and leukemia) that have returned or not responded to prior treatments. The main goals are to find the safest dose and understand how t…
Matched conditions: CLL/SLL
Phase: PHASE1 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC